Journal of Oncology / 2010 / Article / Tab 1

Clinical Study

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

Table 1

Patient characteristics (N=44).

N (%)

Age, yearsMedian63.0
Range33–81
SexMale31 (70.5%)
Female13 (29.5%)
ECOG performance status024 (54.5%)
115 (34.1%)
25 (11.4%)
Primary siteColon22 (50.0%)
Rectum20 (45.5%)
Colorectal2 (4.5%)
Metastatic sitesLiver31 (70.5%)
Lung18 (40.9%)
Lymph nodes8 (18.2%)
Other (mediastinum, pelvis, perineum)4 (9.1%)
Peritoneum2 (4.5%)
Number of target lesions111 (25.0%)
212 (27.3%)
310 (22.7%)
4 or more11 (25.0%)
Prior therapySurgery38 (86.4%)
Radiotherapy11 (25.0%)
Chemotherapy
 Metastatic44 (100.0%)
Time from initial diagnosis to inclusion, monthsMedian17.0
Range2.8–81.1

Abbreviation: ECOG: Eastern Cooperative Oncology Group.